Barriers and Facilitators for Population Genetic Screening in Healthy Populations: A Systematic Review.
| العنوان: | Barriers and Facilitators for Population Genetic Screening in Healthy Populations: A Systematic Review. |
|---|---|
| المؤلفون: | Shen EC; College of Arts and Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.; UNC Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, NC, United States., Srinivasan S; Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States., Passero LE; Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States., Allen CG; Department of Public Health Science, College of Medicine, Medical University of South Carolina, Charleston, SC, United States., Dixon M; Department of Behavioral, Social, and Health Education Science, Rollins School of Public Health, Emory University, Atlanta, GA, United States., Foss K; Department of Genetics, School of Medicine, University of North Carolina, Chapel Hill, NC, United States., Halliburton B; College of Arts and Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Milko LV; Department of Genetics, School of Medicine, University of North Carolina, Chapel Hill, NC, United States., Smit AK; The Daffodil Centre, University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW, Australia.; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia., Carlson R; Health Sciences Library, University of North Carolina, Chapel Hill, NC, United States., Roberts MC; Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States. |
| المصدر: | Frontiers in genetics [Front Genet] 2022 Jul 04; Vol. 13, pp. 865384. Date of Electronic Publication: 2022 Jul 04 (Print Publication: 2022). |
| نوع المنشور: | Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101560621 Publication Model: eCollection Cited Medium: Print ISSN: 1664-8021 (Print) Linking ISSN: 16648021 NLM ISO Abbreviation: Front Genet Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation. |
| مستخلص: | Studies suggest that 1-3% of the general population in the United States unknowingly carry a genetic risk factor for a common hereditary disease. Population genetic screening is the process of offering otherwise healthy patients in the general population testing for genomic variants that predispose them to diseases that are clinically actionable, meaning that they can be prevented or mitigated if they are detected early. Population genetic screening may significantly reduce morbidity and mortality from these diseases by informing risk-specific prevention or treatment strategies and facilitating appropriate participation in early detection. To better understand current barriers, facilitators, perceptions, and outcomes related to the implementation of population genetic screening, we conducted a systematic review and searched PubMed, Embase, and Scopus for articles published from date of database inception to May 2020. We included articles that 1) detailed the perspectives of participants in population genetic screening programs and 2) described the barriers, facilitators, perceptions, and outcomes related to population genetic screening programs among patients, healthcare providers, and the public. We excluded articles that 1) focused on direct-to-consumer or risk-based genetic testing and 2) were published before January 2000. Thirty articles met these criteria. Barriers and facilitators to population genetic screening were organized by the Social Ecological Model and further categorized by themes. We found that research in population genetic screening has focused on stakeholder attitudes with all included studies designed to elucidate individuals' perceptions. Additionally, inadequate knowledge and perceived limited clinical utility presented a barrier for healthcare provider uptake. There were very few studies that conducted long-term follow-up and evaluation of population genetic screening. Our findings suggest that these and other factors, such as prescreen counseling and education, may play a role in the adoption and implementation of population genetic screening. Future studies to investigate macro-level determinants, strategies to increase provider buy-in and knowledge, delivery models for prescreen counseling, and long-term outcomes of population genetic screening are needed for the effective design and implementation of such programs. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020198198. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Shen, Srinivasan, Passero, Allen, Dixon, Foss, Halliburton, Milko, Smit, Carlson and Roberts.) |
| References: | BMC Womens Health. 2017 Dec 16;17(1):132. (PMID: 29246147) Pharmacogenomics J. 2016 Aug;16(4):393-8. (PMID: 26261062) Public Health Genomics. 2014;17(2):95-104. (PMID: 24577154) J Med Ethics. 2020 May 20;:. (PMID: 32434901) JAMA. 2020 Jan 28;323(4):307-308. (PMID: 31808788) Health Psychol. 2018 Dec;37(12):1134-1144. (PMID: 30307272) PLoS Med. 2016 Nov 29;13(11):e1002185. (PMID: 27898672) Front Genet. 2019 Sep 11;10:789. (PMID: 31572433) Genet Med. 2019 Mar;21(3):525-533. (PMID: 30100612) BMJ. 2016 Mar 15;352:i1102. (PMID: 26979548) Eur J Hum Genet. 2003 Aug;11(8):565-72. (PMID: 12891376) Am J Med Genet C Semin Med Genet. 2008 Feb 15;148C(1):78-83. (PMID: 18200522) Int J Technol Assess Health Care. 2006 Summer;22(3):327-37. (PMID: 16984061) Cancers (Basel). 2021 Jun 23;13(13):. (PMID: 34201795) Clin Genet. 2015 Feb;87(2):117-23. (PMID: 24720448) BMC Med Genomics. 2017 Feb 21;10(1):9. (PMID: 28222731) J Health Psychol. 2001 Jul;6(4):405-23. (PMID: 22049389) JAMA. 2021 Aug 17;326(7):621-627. (PMID: 34402850) Nature. 2020 Oct;586(7831):683-692. (PMID: 33116284) Genet Test Mol Biomarkers. 2010 Dec;14(6):847-50. (PMID: 20979574) Transl Behav Med. 2013 Mar 1;3(1):17-29. (PMID: 23565131) JAMA Cardiol. 2020 Feb 1;5(2):217-229. (PMID: 31895433) Front Public Health. 2018 Sep 04;6:247. (PMID: 30234091) Genes Nutr. 2012 Oct;7(4):559-66. (PMID: 22407352) Ann Intern Med. 2017 Jun 27;167(3):159-169. (PMID: 28654958) BMC Pediatr. 2018 Jul 9;18(1):225. (PMID: 29986673) BMC Med Inform Decis Mak. 2007 Jun 15;7:16. (PMID: 17573961) Cancers (Basel). 2021 Aug 12;13(16):. (PMID: 34439206) Liver Int. 2008 Mar;28(3):363-9. (PMID: 18290779) Eur J Hum Genet. 2016 Jan;24(1):14-20. (PMID: 26036856) Nat Med. 2019 Jan;25(1):37-43. (PMID: 30617331) Public Health Genomics. 2015;18(2):104-12. (PMID: 25612474) J Genet Couns. 2015 Dec;24(6):908-21. (PMID: 25735442) Cancer Prev Res (Phila). 2020 Aug;13(8):643-648. (PMID: 32409595) Genet Med. 2003 Jan-Feb;5(1):49-54. (PMID: 12544476) Genome Med. 2019 Feb 27;11(1):10. (PMID: 30808425) BJGP Open. 2019 Feb 20;3(1):bjgpopen18X101633. (PMID: 31049413) BMC Public Health. 2017 May 25;17(1):503. (PMID: 28545429) J Genet Couns. 2019 Apr;28(2):428-437. (PMID: 30835913) Gynecol Oncol. 2019 Aug;154(2):383-387. (PMID: 31239069) Cancer Prev Res (Phila). 2011 Jan;4(1):1-5. (PMID: 21205737) J Gen Intern Med. 2011 Aug;26(8):834-40. (PMID: 21311998) J Genet Couns. 2019 Apr;28(2):438-448. (PMID: 30964585) Health Educ Behav. 2012 Jun;39(3):364-72. (PMID: 22267868) JAMA Dermatol. 2018 Jun 1;154(6):684-693. (PMID: 29801061) Eur J Hum Genet. 2020 May;28(5):551-557. (PMID: 31804631) Eur J Hum Genet. 2015 Jan;23(1):8-21. (PMID: 24848746) BMJ. 2009 Jul 21;339:b2535. (PMID: 19622551) J Genet Couns. 2018 Apr;27(2):370-380. (PMID: 29199389) Genet Med. 2021 Dec;23(12):2394-2403. (PMID: 34385669) Public Health Genomics. 2011;14(4-5):238-47. (PMID: 20090298) Eur J Hum Genet. 2017 Feb;25(3):280-292. (PMID: 28051073) Eur J Hum Genet. 2020 Dec;28(12):1631-1644. (PMID: 32948847) Prev Med. 2004 Sep;39(3):458-64. (PMID: 15313084) BMC Med Genomics. 2016 May 23;9(1):25. (PMID: 27215612) Pharmacogenomics. 2017 Jul;18(10):1013-1025. (PMID: 28639489) J Mol Diagn. 2016 Sep;18(5):605-619. (PMID: 27542512) Health Aff (Millwood). 2018 May;37(5):793-800. (PMID: 29733703) |
| معلومات مُعتمدة: | K00 CA253576 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: attitudes; average risk; healthy population screening; outcomes; perceptions; population testing; precision public health; universal genetic screening |
| تواريخ الأحداث: | Date Created: 20220721 Latest Revision: 20230317 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9289280 |
| DOI: | 10.3389/fgene.2022.865384 |
| PMID: | 35860476 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1664-8021 |
|---|---|
| DOI: | 10.3389/fgene.2022.865384 |